The brain erythropoietin cycle as driver of adaptive neuroplasticity via functional hypoxia
The BREPOCI project aims to investigate the procognitive effects of recombinant human EPO on brain cell maturation and plasticity, targeting neuropsychiatric conditions linked to cognitive decline.
Projectdetails
Introduction
Cognitive disability and decline play key roles in neuropsychiatric conditions but lack effective therapies. Erythropoietin (EPO) is a hypoxia-inducible growth factor, named after its original description in erythropoiesis.
Discovery of EPO Effects
We discovered - by 'reverse approach' (human trials first) - that recombinant human (rh) EPO has potent procognitive effects, hematopoiesis-independent.
Mechanistic Insights
Searching for mechanistic insight in mice, we saw that rhEPO markedly drives differentiation/maturation of pyramidal neurons and oligodendrocytes from non-dividing precursors in cornu ammonis, outside known neurogenesis areas.
In parallel, rhEPO dampens microglia. This suggests that endogenous, brain-expressed EPO (bEPO), acting in an auto/paracrine fashion, has fundamental, hitherto overlooked physiological significance.
Groundbreaking Hypotheses
BREPOCI will pursue the groundbreaking hypotheses that:
- 'Functional hypoxia' is a physiological consequence of increased neuronal activity, inciting an integrated response of many brain cell types.
- This activity-induced hypoxia stimulates bEPO expression to optimize multicellular brain plasticity, providing substantial 'hardware upgrade'.
- BREPOCI postulates diverse EPOR in the brain and will study their nature and contribution to these pivotal processes upon normoxia, 'functional', and inspiratory hypoxia.
- rhEPO treatment of intellectual disability/autism caused by Tbr1 or Zbtb20 loss-of-function mutations will constitute a first mechanistic approach to specific brain pathologies, translatable to humans.
Project Tools and Techniques
This ERC project can build on acquired novel genetic mouse tools, including:
- Cell-type specific EPO/EPOR mutants
- Inducible hypoxia reporters
- Multiomic mice
Additionally, sophisticated behavior tests, MRI/MRS, multiphoton imaging, NanoSIMS, sc/snRNA-seq, confocal/Lightsheet/electron microscopy, and electrophysiology will be utilized.
Objectives
BREPOCI will illuminate rhEPO/bEPO effects on physiological brain functions and explore how it limits developmental delay, intellectual disability, or neurodegeneration.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.495.594 |
Totale projectbegroting | € 2.495.594 |
Tijdlijn
Startdatum | 1-9-2022 |
Einddatum | 31-3-2028 |
Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- ZENTRALINSTITUT FUER SEELISCHE GESUNDHEITpenvoerder
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
- MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Altitude-like hypoxia cognition training to target brain erythropoietin as a novel mechanism of long-lasting enhancement of neuroplasticity and cognitive functionsALTIBRAIN aims to explore the effects of low ambient oxygen on brain EPO levels to enhance neuroplasticity and cognitive function, potentially transforming treatments for cognitive decline. | ERC Consolid... | € 1.999.944 | 2022 | Details |
Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotencyThe project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies. | ERC Advanced... | € 2.500.000 | 2023 | Details |
Drug DELIvery to the brain via CHOroid Plexus targetingThis project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders. | ERC Consolid... | € 1.999.756 | 2024 | Details |
Explore Your Brain 2.0: a maximally effective, usable and scalable growth mindset intervention to break through adolescents’ declining rates of motivation and school achievementsThis project aims to enhance and scale the Explore Your Brain (EYB 2.0) intervention to improve high school students' motivation and resilience through a growth mindset approach. | ERC Proof of... | € 150.000 | 2024 | Details |
What does your blood remember? The memory of hematopoietic stem cells.This project aims to investigate how hematopoietic stem cells develop adaptive memory to environmental stress, enhancing blood cell responses and improving transplantation strategies. | ERC Starting... | € 2.500.000 | 2022 | Details |
Altitude-like hypoxia cognition training to target brain erythropoietin as a novel mechanism of long-lasting enhancement of neuroplasticity and cognitive functions
ALTIBRAIN aims to explore the effects of low ambient oxygen on brain EPO levels to enhance neuroplasticity and cognitive function, potentially transforming treatments for cognitive decline.
Reprogramming of somatic cells into organOids: patient-centred neurodevelopmental disease modelling from nascent induced pluripotency
The project aims to develop a robust method for generating human brain organoids from patients with Fragile X Syndrome to explore neurodevelopmental phenotypes and inform targeted therapies.
Drug DELIvery to the brain via CHOroid Plexus targeting
This project aims to explore the blood-CSF barrier as a novel route for delivering therapeutics to the brain, potentially enhancing treatment strategies for CNS disorders.
Explore Your Brain 2.0: a maximally effective, usable and scalable growth mindset intervention to break through adolescents’ declining rates of motivation and school achievements
This project aims to enhance and scale the Explore Your Brain (EYB 2.0) intervention to improve high school students' motivation and resilience through a growth mindset approach.
What does your blood remember? The memory of hematopoietic stem cells.
This project aims to investigate how hematopoietic stem cells develop adaptive memory to environmental stress, enhancing blood cell responses and improving transplantation strategies.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATIONREGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration. | EIC Pathfinder | € 2.943.233 | 2024 | Details |
Bottom-up reconstruction of a Synthetic ErythrocyteSynEry aims to create a synthetic erythrocyte using advanced lipid vesicles and interdisciplinary methods to address global blood scarcity and safety challenges. | EIC Pathfinder | € 3.685.549 | 2022 | Details |
Homeoproteins as novel therapies for neurodegenerative diseasesBrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the BrainPrometeus aims to personalize nutrition for premature neonates in NICUs through real-time adjustments of glucose and nutrients based on brain needs, reducing the risk of neurodevelopmental disabilities. | EIC Pathfinder | € 3.554.156 | 2023 | Details |
IMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION
REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.
Bottom-up reconstruction of a Synthetic Erythrocyte
SynEry aims to create a synthetic erythrocyte using advanced lipid vesicles and interdisciplinary methods to address global blood scarcity and safety challenges.
Homeoproteins as novel therapies for neurodegenerative diseases
BrainEver is developing a revolutionary therapy using the homeoprotein Engrailed-1 to treat neurodegenerative diseases like ALS and Parkinson's by restoring neuronal function.
Preterm Brain-Oxygenation and Metabolic EU-Sensing: Feed the Brain
Prometeus aims to personalize nutrition for premature neonates in NICUs through real-time adjustments of glucose and nutrients based on brain needs, reducing the risk of neurodevelopmental disabilities.